Uso de simulador de conducción adaptado de bajo costo en entorno de realidad virtual en personas con lesión medular tipo paraplejia. Una serie de casos

Contenido principal del artículo

LUIS ALDANA F
VIVIANO CID S
SERGIO REYES B

Keywords

lesión medular, simulador de conducción, adaptación manual para conducir vehículos, realidad virtual

Resumen

Introducción: La capacidad de conducir un vehículo motorizado impacta en la participación comunitaria de una persona con lesión medular congénita o adquirida. Al respecto, los simuladores de conducción sirven tanto de en­ frenamiento como para determinar la idoneidad para conducir un vehículo motorizado. Objetivo: Describir la experiencia de uso de un simulador de conducción adaptado en entorno de realidad virtual en personas con lesión medular tipo paraplejia de origen congénito o adquirido. Método: Se selec­cionaron 6 usuarios/as con paraplejia congénita o adquirida, entre 18 y 24 años de edad, sin antecedentes de patología visual, con resistencia máxima y sensibilidad completa en miembros superiores. Todos recibieron 8 sesiones de 40 minutos de uso del simulador. Se aplicó evaluación basal, al primero y tercer mes post intervención sobre estado funcional, impacto psicosocial de la asistencia tecnológica (PIADS) y satisfacción usuaria. Resultados: En PIADS, el puntaje para Adaptabilidad es constante con puntuación máxima midiendo en 1 y 3 meses. En el mismo periodo, el puntaje de Competencia sube de 2,6 a 2,7, mientras que Autoestima sube de 2,1 a 2,2 puntos. En la encuesta de satis­facción destaca la valoración máxima y constante en el ítem “Recomendación del simulador”. Ninguno de estos cambios fue estadísticamente significativo. Conclusión: Los cambios observados en las puntuaciones, aun no siendo sig­nificativos, son positivos y consistentes con los antecedentes teóricos respecto a la valoración de la experiencia de uso de simulador de conducción adaptado en entorno de realidad virtual.

Abstract 71 | PDF Downloads 41

Citas

1. Rosenbaum P, Paneth N, Leviton A, Goldstein M, Bax M, Damiano D, Dan B, Jacobsson B. A report: the de- finition and classification of cerebral palsy April 2006. Dev Med Child Neurol Suppl. 2007 Feb;109:8-14
2. Graham HK, Rosenbaum P, Paneth N, Dan B, Lin J-P, Damiano DL, Becher JG, Gaebler-Spira D, Col- ver A, Reddihough DS, Crompton KE, Lieber RL. Cerebral palsy. Nature Reviews Disease Primers. 2016;2(1):15082.
3. Pérez-Salas CP, Ortega A, Parra V, Rosenbaum P. School placement and participation of Chilean young people with cerebral palsy. International Journal of Inclusive Education. 2020:1-20. doi: 10.1080/13603116.2020.1807625.
4. Boyd R, Graham HK. Botulinum toxin A in the management of children with cerebral palsy: indications and outcome. European journal of neurology. 1997.
5. Balzer J, van der Linden ML, Mercer TH, van Hedel HJA. Selective voluntary motor control measures of the lower extremity in children with upper motor neuron lesions: a systematic review. Dev Med Child Neurol. 2017 Jul;59(7):699-705. doi: 10.1111/dmcn.13417. Epub 2017 Mar 8. PMID: 28272744.
6. Richards CL, Malouin F. Cerebral palsy: definition, assessment and rehabilitation. Handb Clin Neurol.
2013;111:183-95.
7. Bar-On L, Molenaers G, Aertbelien E, Van Campenhout A, Feys H, Nuttin B, Desloovere K. Spasticity and its contribution to hypertonia in cerebral palsy. Biomed Res Int. 2015;2015:317047.
8. Prevalence and characteristics of children with cere¬bral palsy in Europe. Dev Med Child Neurol. 2002 Sep;44(9):633-40.
9. Hoare BJ, Wallen MA, Imms C, Villanueva E, Rawic- ki HB, Carey L. Botulinum toxin A as an adjunct to treatment in the management of the upper limb in chil- dren with spastic cerebral palsy (UPDATE). Cochrane Database Syst Rev. 2010 Jan 20;2010(1):CD003469. doi: 10.1002/14651858.CD003469.pub4. PMID: 20091546; PMCID: PMC7154577.
10. Instituto de Salud Pública, Chile. Folleto de Información al Profesional. Botox polvo para solución inyectable 50 U. 2013. [Acceso: 04 Enero 2021]. Disponible en: http://www.ispch.cl/sites/default/files/toxina_botulini- ca_tipo_a_50u.pdf
11. Ackman JD, Russman BS, Thomas SS, Buckon CE, Sussman MD, Masso P, Sanders J, D’Astous J, Aiona MD. Comparing botulinum toxin A with casting for treatment of dynamic equinus in children with cerebral palsy. Developmental medicine and child neurology. 2005;47(9):620-7. Epub 2005/09/06.
12. Reddihough DS, King JA, Coleman GJ, Fosang A, Mc- Coy AT, Thomason P, Graham HK. Functional outcome of botulinum toxin A injections to the lower limbs in cerebral palsy. Developmental medicine and child neu- rology. 2002;44(12):820-7. Epub 2002/11/29.
13. Centre for Evidence-Based Medicine. OCEBM Levels of Evidence. [Acceso: 04 Enero 2021]. Disponible en: https://www.cebm.ox.ac.uk/resources/levels-of- evidence/ocebm-levels-of-evidence.
14. Blasi J, Chapman ER, Link E, Binz T, Yamasaki S, De Camilli P, Südhof TC, Niemann H, Jahn R. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature. 1993 Sep 9;365(6442):160-3.
15. Graham HK, Aoki KR, Autti-Ramo I, Boyd RN, Del¬gado MR, Gaebler-Spira DJ, Gormley ME, Guyer BM, Heinen F, Holton AF, Matthews D, Molenaers G, Motta F, Garcia Ruiz PJ, Wissel J. Recommendations for the use of botulinum toxin type A in the management of cerebral palsy. Gait & posture. 2000;11(1):67-79. Epub 2000/02/09.
16. Kay RM, Rethlefsen SA, Fern-Buneo A, Wren TA, Skaggs DL. Botulinum toxin as an adjunct to serial casting treatment in children with cerebral palsy. The Journal of bone and joint surgery American volume. 2004;86-A(11):2377-84. Epub 2004/11/04.
17. Esquenazi A, Alfaro A, Ayyoub Z, Charles D, Das- htipour K, Graham GD, McGuire JR, Odderson IR, Patel AT, Simpson DM. OnabotulinumtoxinA for Lower Limb Spasticity: Guidance From a Delphi Panel Approach. PM & R : the journal of injury, function, and rehabilitation. 2017;9(10):960-8. Epub 2017/03/14.
18. Esquenazi A, Novak I, Sheean G, Singer BJ, Ward AB. International consensus statement for the use of botuli- num toxin treatment in adults and children with neuro- logical impairments--introduction. European journal of neurology. 2010;17 Suppl 2:1-8. Epub 2010/07/17. doi: 10.1111/j.1468-1331.2010.03125.x. PubMed PMID: 20633176.
19. Strobl W, Theologis T, Brunner R, Kocer S, Viehweger E, Pascual-Pascual I, Placzek R. Best clinical practice in botulinum toxin treatment for children with cerebral pal- sy. Toxins. 2015;7(5):1629-48. Epub 2015/05/15.
20. Schwabe AL. Botulinum Toxin in the Treatment of Pe- diatric Upper Limb Spasticity. Semin Plast Surg. 2016 Feb;30(1):24-8.
21. Love S, Novak I, Kentish M, Desloovere K, Heinen F, Molenaers G, O’flaherty S, Graham H. Botulinum toxin assessment, intervention and after-care for lower limb spasticity in children with cerebral palsy: international consensus statement. European journal of neurology. 2010;17:9-37.
22. Sutherland DH, Kaufman KR, Wyatt MP, Chambers HG, Mubarak SJ. Double-blind study of botulinum A to- xin injections into the gastrocnemius muscle in patients with cerebral palsy. Gait & posture. 1999;10(1):1-9.
23. Esquenazi A, Albanese A, Chancellor MB, Elovic E, Se¬gal KR, Simpson DM, Smith CP, Ward AB. Evidence- based review and assessment of botulinum neurotoxin for the treatment of adult spasticity in the upper motor neuron syndrome. Toxicon : official journal of the International Society on Toxinology. 2013;67:115-28. Epub 2012/12/12.
24. Olver J, Esquenazi A, Fung VS, Singer BJ, Ward AB. Botulinum toxin assessment, intervention and aftercare for lower limb disorders of movement and muscle tone in adults: international consensus statement. European journal of neurology. 2010;17 Suppl 2:57-73. Epub 2010/07/17.
25. Yang EJ, Rha DW, Kim HW, Park ES. Comparison of botulinum toxin type A injection and soft-tissue sur- gery to treat hip subluxation in children with cerebral palsy. Archives of physical medicine and rehabilitation. 2008;89(11):2108-13. Epub 2008/11/11.
26. Lowe K, Novak I, Cusick A. Repeat injection of botulinum toxin A is safe and effective for upper limb movement and function in children with cerebral palsy. Developmental medicine and child neuro- logy. 2007;49(11):823-9. Epub 2007/11/06.
27. Molenaers G, Desloovere K, Fabry G, De Cock P. The effects of quantitative gait assessment and botulinum toxin a on musculoskeletal surgery in children with ce¬rebral palsy. The Journal of bone and joint surgery Ame- rican volume. 2006;88(1):161-70. Epub 2006/01/05.
28. Fonseca PR, Jr., Calhes Franco de Moura R, Galli M, Santos Oliveira C. Effect of physiotherapeutic interven- tion on the gait after the application of botulinum toxin in children with cerebral palsy: systematic review. Eu- ropean journal of physical and rehabilitation medicine. 2018;54(5):757-65. Epub 2017/12/01.
29. Hong BY, Chang HJ, Lee SJ, Lee S, Park JH, Kwon JY. Efficacy of Repeated Botulinum Toxin Type A Injections for Spastic Equinus in Children with Cere¬bral Palsy-A Secondary Analysis of the Randomized Clinical Trial. Toxins. 2017;9(8). Epub 2017/08/22.
30. Dumas HM, O’Neil M E, Fragala MA. Expert consen- sus on physical therapist intervention after botulinum toxin a injection for children with cerebral palsy. Pediatric physical therapy : the official publication of the Section on Pediatrics of the American Physical Therapy Association. 2001;13(3):122-32. Epub 2006/10/21.
31. Gobbo M, Maffiuletti NA, Orizio C, Minetto MA. Mus- cle motor point identification is essential for optimizing neuromuscular electrical stimulation use. J Neuroeng Rehabil. 2014 Feb 25;11:17.
32. Dai AI, Demiryurek AT. Serial Casting as an Adjunct to Botulinum Toxin Type A Treatment in Children With Cerebral Palsy and Spastic Paraparesis With Scissoring of the Lower Extremities. Journal of child neurology. 2017;32(7):671-5. Epub 2017/04/11.
33. Novak I, McIntyre S, Morgan C, Campbell L, Dark L, Morton N, Stumbles E, Wilson SA, Goldsmith S. A systematic review of interventions for children with cerebral palsy: state of the evidence. Developmental medicine and child neurology. 2013;55(10):885-910. Epub 2013/08/22.
34. Heinen F, Desloovere K, Schroeder AS, Berweck S, Borggraefe I, van Campenhout A, Andersen GL, Aydin R, Becher JG, Bernert G, Caballero IM, Carr L, Valayer EC, Desiato MT, Fairhurst C, Filipetti P, Hassink RI, Hustedt U, Jozwiak M, Kocer SI, Kolanowski E, Krageloh-Mann I, Kutlay S, Maenpaa H, Mall V, McArthur P, Morel E, Papavassiliou A, Pascual-Pascual I, Pedersen SA, Plasschaert FS, van der Ploeg I, Remy- Neris O, Renders A, Di Rosa G, Steinlin M, Tedroff K, Valls JV, Viehweger E, Molenaers G. The updated European Consensus 2009 on the use of Botulinum toxin for children with cerebral palsy. European journal of paediatric neurology : EJPN : official journal of the European Paediatric Neurology Society. 2010;14(1):45- 66. Epub 2009/11/17
35. Placzek R, Siebold D, Funk JF. Development of treatment concepts for the use of botulinum toxin a in children with cerebral palsy. Toxins. 2010;2(9):2258-71.
36. National Institute for Health and Care Excelence. Spas- ticity in Under 19s: Management UK 2016. [Acceso: 04 Enero 2021]. Disponible en: https://www.nice.org.uk/guidance/cg145/resources/spasticity-in-under-19s-management-pdf-35109572514757 .
37. National Guideline Alliance (UK). Cerebral palsy in un- der 25s: assessment and management. London: National Institute for Health and Care Excellence (UK). 2017 Jan. (NICE Guideline, No. 62.) Disponible en:
https://www.ncbi.nlm.nih.gov/books/NBK419326/
38. Multani I, Manji J, Tang MJ, Herzog W, Howard JJ, Graham HK. Sarcopenia, Cerebral Palsy, and Botuli- num Toxin Type A. JBJS Rev. 2019 Aug;7(8):e4.
39. Aydin A, Memisoglu K, Cengiz A, Atmaca H, Muezzinoglu B, Muezzinoglu US. Effects of botulinum toxin A on fracture healing in rats: an experimental study. Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association. 2012;17(6):796-801. Epub 2012/07/25.
40. Paulson A, Zigler CK, Houtrow A, Pruitt D. Botulinum Toxin: Techniques Within Pediatric Physiatry. Pm&r. 2019;11(1):38-44.
41. Chin FYP. Duncan JA, Johnstone BR, et al. Managment of upper limb in cerebral palsy. J pediatrics OrthopedicB 2005; 14.389-404.